<DOC>
	<DOCNO>NCT01357811</DOCNO>
	<brief_summary>The primary objective study determine effect repeat oral dos eliglustat 150 mg twice daily ( BID ) ( 100 mg BID CYP2D6 poor metabolizers ) pharmacokinetics ( PK ) orally administer digoxin 0.25 mg healthy adult subject . This single-site , open-label study 2 stagger cohort healthy adult subject . The study comprise screen period ( Day -45 Day -2 ) , treatment period 1 ( Day -1 Day 4 ) , treatment period 2 ( Day 11 Day 18 ) , safety follow-up visit ( Day 24 ± 1 ) . There 10-day washout dose study drug Period 1 Period 2 . The duration subject 's participation study , inclusive screen follow-up visit , approximately 10 week .</brief_summary>
	<brief_title>A Phase 1 Study Evaluating Eliglustat 's Effects Pharmacokinetics , Safety &amp; Tolerability Digoxin Healthy Adults</brief_title>
	<detailed_description>Cohort 1 comprise 10 subject Cohort 2 comprise 18 subject . Initiation treatment Cohort 1 occur least 6 day prior start treatment Cohort 2 . In cohort , eligible subject admit clinical facility Day -1 , day prior start dose Period 1 , remain clinic completion study procedure Day 18 , last day Period 2 ( approximately 18-night inpatient stay ) . In Period 1 , subject receive single oral dose digoxin 0.25 mg Day 1 . In Period 2 , subject receive repeat oral dos eliglustat 150 mg BID ( 100 mg BID CYP2D6 poor metabolizer ) Day 11 Day 17 single oral dose digoxin 0AA mg Day 15 . For Cohort 2 , co-administration digoxin eliglustat Day 15 occur review safety data ( include telemetry data ) least Day 16 subject Cohort 1 . The decision proceed concomitant dose subject Cohort 2 discretion Investigator , consultation Sponsor , appropriate .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>The male female subject good general health The subject body weight 50 100 kg ( 110 220 lb ) body mass index ( BMI ) ≤32 kg/m2 screening . The subject 's physical examination , laboratory , vital sign , electrocardiogram ( ECG ) test result within normal limit screen Day 1 , abnormal , consider clinically significant opinion Investigator . The subject nonsmoker least 6 month prior time provide informed consent , willing able abstain smoking ( use form nicotine ) completion safety followup visit . The subject use drug abuse least 6 month prior Day 1 willing able abstain use drug abuse completion safety followup visit . The subject willing able abstain alcohol 48 hour prior first dose study drug completion safety followup visit . The subject willing able abstain grapefruit grapefruit juice 72 hour prior first dose study drug completion safety followup visit . The subject willing able maintain normalfiber diet ( i.e. , abstain excess fiberrich food ) 72 hour prior first dose study drug completion safety followup visit . Female subject childbearing potential must document negative pregnancy test screen Day 1 , willing use medically accept form contraception ( define protocol ) screen 30 day last dose study drug . A woman childbearing potential define female amenorrheic least 2 year undergone hysterectomy surgical sterilization . The subject following : Clinically significant coronary artery disease include history myocardial infarction ongoing sign symptom consistent cardiac ischemia heart failure ; clinically significant arrhythmias conduction defect 2nd 3rd degree atrioventricular ( AV ) block , PR interval ≥210 msec , complete bundle branch block , prolong QTc interval ( e.g. , repeated demonstration QTc interval ≥450 msec ) , sustain ventricular tachycardia . The subject receive antibiotic reason within 30 day prior first dose study drug . The subject receive prescription nonprescription medication ( exception nonprescriptionstrength ibuprofen acetaminophen ) dietary herbal fiber supplement within 30 day 5 halflives ( whichever longer ) prior first dose study drug without approval Investigator Genzyme . The subject receive immunization within 30 day provide informed consent . The subject history hypersensitivity digoxin digitalis glycoside , drug allergy clinically significant opinion Investigator ( e.g. , significant rash hive ) . The subject clinically significant organic disease , include cardiovascular , renal , hepatic , gastrointestinal , pulmonary , neurologic , endocrine , metabolic , psychiatric disease , medical condition electrolyte disorder , serious intercurrent illness , extenuate circumstance , opinion Investigator , preclude participation trial . The subject digestive disorder , include malabsorption , gastroenteritis , pancreatitis , constipation , gastroesophageal reflux disease , diverticulitis , irritable bowel syndrome , inflammatory bowel disease ( include Crohn 's disease ) . The subject cholecystectomy . The subject screening laboratory test result &gt; 2x upper limit normal ( ULN ) follow liver function test : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyltransferase ( GGT ) , total bilirubin . The subject test positive human immunodeficiency virus ( HIV ) antibody , hepatitis C antibody , hepatitis B surface antigen screening . The subject test positive urine drug abuse , urine alcohol , urine cotinine screening . The subject receive investigational product within 30 day prior provide inform consent plan receive investigational product time course study . The subject donate blood blood product within 30 day prior provide inform consent . The subject 's schedule travel plan prevent completion require visit . The subject schedule inpatient hospitalization , include elective surgery ( inpatient outpatient ) , study . The subject history cancer , exception basal cell carcinoma . The female subject childbearing potential pregnant lactating . The subject , opinion Investigator , unable adhere requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Genz-112638</keyword>
	<keyword>digoxin</keyword>
</DOC>